Array-Based DNA Methylation Profiling for Breast Cancer Subtype Discrimination

Background Abnormal DNA methylation is well established for breast cancer and contributes to its progression by silencing tumor suppressor genes. DNA methylation profiling platforms might provide an alternative approach to expression microarrays for accurate breast tumor subtyping. We sought to determine whether the distinction of the inflammatory breast cancer (IBC) phenotype from the non-IBC phenotype by transcriptomics could be sustained by methylomics. Methodology/Principal Findings We performed methylation profiling on a cohort of IBC (N = 19) and non-IBC (N = 43) samples using the Illumina Infinium Methylation Assay. These results were correlated with gene expression profiles. Methylation values allowed separation of breast tumor samples into high and low methylation groups. This separation was significantly related to DNMT3B mRNA levels. The high methylation group was enriched for breast tumor samples from patients with distant metastasis and poor prognosis, as predicted by the 70-gene prognostic signature. Furthermore, this tumor group tended to be enriched for IBC samples (54% vs. 24%) and samples with a high genomic grade index (67% vs. 38%). A set of 16 CpG loci (14 genes) correctly classified 97% of samples into the low or high methylation group. Differentially methylated genes appeared to be mainly related to focal adhesion, cytokine-cytokine receptor interactions, Wnt signaling pathway, chemokine signaling pathways and metabolic processes. Comparison of IBC with non-IBC led to the identification of only four differentially methylated genes (TJP3, MOGAT2, NTSR2 and AGT). A significant correlation between methylation values and gene expression was shown for 4,981 of 6,605 (75%) genes. Conclusions/Significance A subset of clinical samples of breast cancer was characterized by high methylation levels, which coincided with increased DNMT3B expression. Furthermore, an association was observed with molecular signatures indicative of poor patient prognosis. The results of the current study also suggest that aberrant DNA methylation is not the main force driving the molecular biology of IBC.

[1]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[3]  Mariano Provencio,et al.  Promoter methylation of the PTEN gene is a common molecular change in breast cancer , 2004, Genes, chromosomes & cancer.

[4]  N. Seki,et al.  CpG hypermethylation of collagen type I alpha 2 contributes to proliferation and migration activity of human bladder cancer. , 2009, International journal of oncology.

[5]  J. Herman,et al.  CpG island methylator phenotype in colorectal cancer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J. Herman,et al.  Hypermethylation in Histologically Distinct Classes of Breast Cancer , 2004, Clinical Cancer Research.

[7]  Johan Staaf,et al.  Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns , 2010, Breast Cancer Research.

[8]  G. Kristiansen,et al.  Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis , 2006, Oncogene.

[9]  J. Ragoussis,et al.  CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma , 2009, Molecular Cancer.

[10]  Xin Hu,et al.  Correlation between CpG methylation profiles and hormone receptor status in breast cancers , 2007, Breast Cancer Research.

[11]  B. X. Trinh,et al.  Aberrant methylation of the Adenomatous Polyposis Coli (APC) gene promoter is associated with the inflammatory breast cancer phenotype , 2008, British Journal of Cancer.

[12]  A. Feinberg,et al.  The history of cancer epigenetics , 2004, Nature Reviews Cancer.

[13]  Hung D. Nguyen,et al.  DNA methylation differences associated with tumor tissues identified by genome scanning analysis. , 1998, Genomics.

[14]  Xianrang Song,et al.  Down-regulation of CXCL12 mRNA expression by promoter hypermethylation and its association with metastatic progression in human breast carcinomas , 2008, Journal of Cancer Research and Clinical Oncology.

[15]  J. Herman,et al.  Gene silencing in cancer in association with promoter hypermethylation. , 2003, The New England journal of medicine.

[16]  E. van Marck,et al.  Quantitative assessment of DNA hypermethylation in the inflammatory and non-inflammatory breast cancer phenotypes , 2009, Cancer biology & therapy.

[17]  M. Esteller,et al.  Epigenetic biomarkers for human cancer: the time is now. , 2008, Critical reviews in oncology/hematology.

[18]  Martin Widschwendter,et al.  Association of Breast Cancer DNA Methylation Profiles with Hormone Receptor Status and Response to Tamoxifen , 2004, Cancer Research.

[19]  Masaru Shinozaki,et al.  Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors , 2008, Breast Cancer Research.

[20]  Donald L Weaver,et al.  Revision of the American Joint Committee on Cancer staging system for breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  W. Jones,et al.  DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines , 2008, Molecular Cancer.

[22]  P. Corvol,et al.  Angiotensinogen delays angiogenesis and tumor growth of hepatocarcinoma in transgenic mice. , 2009, Cancer research.

[23]  M. Wendt,et al.  Epigenetic silencing of CXCL12 increases the metastatic potential of mammary carcinoma cells , 2008, Oncogene.

[24]  K. Sugano,et al.  Distinct methylated profiles in Helicobacter pylori dependent and independent gastric MALT lymphomas , 2003, Gut.

[25]  B. Iacopetta,et al.  DNA hypermethylation in breast cancer and its association with clinicopathological features. , 2006, Cancer letters.

[26]  M. J. van de Vijver,et al.  Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. , 2006, Journal of the National Cancer Institute.

[27]  R. Palmqvist,et al.  The Role of the CpG Island Methylator Phenotype in Colorectal Cancer Prognosis Depends on Microsatellite Instability Screening Status , 2010, Clinical Cancer Research.

[28]  P. Opolon,et al.  Suppression of angiogenesis, tumor growth, and metastasis by adenovirus-mediated gene transfer of human angiotensinogen. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[29]  Luc Y Dirix,et al.  Increased Angiogenesis and Lymphangiogenesis in Inflammatory versus Noninflammatory Breast Cancer by Real-Time Reverse Transcriptase-PCR Gene Expression Quantification , 2004, Clinical Cancer Research.

[30]  H. Sasano,et al.  Promoter methylation status of the Cyclin D2 gene is associated with poor prognosis in human epithelial ovarian cancer , 2007, Cancer science.

[31]  Randy D. Gascoyne,et al.  Array-based DNA methylation profiling in follicular lymphoma , 2009, Leukemia.

[32]  G. Hortobagyi,et al.  Inflammatory breast cancer: a review. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. Herman,et al.  Aberrant methylation of gene promoters in cancer---concepts, misconcepts, and promise. , 2000, Journal of the National Cancer Institute.

[34]  K. Ohshima,et al.  Multi-step aberrant CpG island hyper-methylation is associated with the progression of adult T-cell leukemia/lymphoma. , 2010, The American journal of pathology.

[35]  A. Kaneda,et al.  CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. , 2005, Cancer research.

[36]  S. Baylin,et al.  Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. , 1999, Cancer research.

[37]  Robert Brown,et al.  Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. , 2001, The American journal of pathology.

[38]  P. Laird,et al.  Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. , 2000, Cancer research.

[39]  E. van Marck,et al.  Relapse-Free Survival in Breast Cancer Patients Is Associated with a Gene Expression Signature Characteristic for Inflammatory Breast Cancer , 2008, Clinical Cancer Research.

[40]  G. Watkins,et al.  Loss of tight junction plaque molecules in breast cancer tissues is associated with a poor prognosis in patients with breast cancer. , 2004, European journal of cancer.

[41]  R H Hruban,et al.  Hypermethylation of multiple genes in pancreatic adenocarcinoma. , 2000, Cancer research.

[42]  E. van Marck,et al.  Distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using Affymetrix-based genome-wide gene-expression analysis , 2007, British Journal of Cancer.

[43]  Yun-fei Yuan,et al.  CpG Island Methylator Phenotype Associated with Tumor Recurrence in Tumor–Node–Metastasis Stage I Hepatocellular Carcinoma , 2010, Annals of Surgical Oncology.

[44]  Peter A. Jones,et al.  Epigenetics in cancer. , 2010, Carcinogenesis.

[45]  R. Jensen,et al.  Neuropeptides as autocrine growth factors in cancer cells. , 2003, Current pharmaceutical design.

[46]  S. Clark,et al.  Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. , 1999, Cancer research.

[47]  Nita Ahuja,et al.  DNA methylation and environmental exposures in human hepatocellular carcinoma. , 2002, Journal of the National Cancer Institute.

[48]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[49]  E. van Marck,et al.  Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression , 2003, British Journal of Cancer.

[50]  M. Esteller.  CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future , 2002, Oncogene.

[51]  M. Fackler,et al.  DNA methylation of RASSF1A, HIN‐1, RAR‐β, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma , 2003, International journal of cancer.

[52]  H. Aburatani,et al.  Three DNA Methylation Epigenotypes in Human Colorectal Cancer , 2009, Clinical Cancer Research.

[53]  D. Morton,et al.  CpG Island Methylator Phenotype Predicts Progression of Malignant Melanoma , 2009, Clinical Cancer Research.

[54]  Shuji Ogino,et al.  DNMT3B Expression Might Contribute to CpG Island Methylator Phenotype in Colorectal Cancer , 2009, Clinical Cancer Research.

[55]  Wei Jiang,et al.  High-throughput DNA methylation profiling using universal bead arrays. , 2006, Genome research.

[56]  S. Merajver,et al.  Molecular biology of breast cancer metastasis: Inflammatory breast cancer: clinical syndrome and molecular determinants , 2000, Breast Cancer Research.

[57]  E. Dahl,et al.  Epigenetic inactivation of the secreted frizzled-related protein-5 (SFRP5) gene in human breast cancer is associated with unfavorable prognosis. , 2008, Carcinogenesis.